Markets:

Overview

News

Currencies

International

Treasuries

IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

28.32 +0.11 (+0.39%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about IDEAYA Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data ↗

May 18, 2026

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also...

Via MarketBeat

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

May 14, 2026

From USA News Group

Via GlobeNewswire

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

April 13, 2026

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial.

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

April 10, 2026

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

IDEAYA Biosciences Inc (NASDAQ:IDYA) Shows Strong Technical Setup for Potential Breakout ↗

December 22, 2025

IDEAYA Biosciences (IDYA) shows strong technical health and a high-quality breakout setup, indicating potential for a continued advance.

Via Chartmill

SLB To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 21, 2025

Via Benzinga

Buying IDEAYA Might Be The Wrong IDYA Right Now ↗

September 16, 2025

IDEAYA Stock's Adhishthana.com cycle signals prolonged weakness after a failed Cakra, with underperformance likely until May 2029.

Via Benzinga

Alibaba To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 29, 2025

Via Benzinga

IDEAYA (IDYA) Q2 Net Loss Improves 27% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

This Royal Caribbean Cruises Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗

July 22, 2025

Via Benzinga

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

June 26, 2025

Via Benzinga

This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 26, 2025

Via Benzinga

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It ↗

November 15, 2024

Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38.

Via Benzinga

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

November 11, 2024

From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Via Business Wire

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 05, 2024

Via Benzinga

Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate ↗

September 23, 2024

IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates.

Via Benzinga

Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

September 10, 2024

Via Benzinga

IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 ↗

August 06, 2024

IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal ↗

August 03, 2024

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,...

Via Talk Markets

MarketBeat Week in Review – 7/15 - 7/19

July 20, 2024

Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next

Via MarketBeat

Topics Economy

Positive News is Driving This Cancer Drug Maker’s Stock Higher

July 15, 2024

IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather

Via MarketBeat

Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 10, 2024

Via Benzinga

Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 10, 2024

Via Benzinga

Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 08, 2024

Via Benzinga

IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer ↗

July 08, 2024

IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a...

Via Benzinga

Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday ↗

July 08, 2024

Via Benzinga

Why Ideaya Biosciences Just Made Its Most Bullish Move Since March ↗

July 08, 2024

The company is working on a treatment for cancers tied to a genetic alteration called MTAP deletion.

Via Investor's Business Daily

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.